Jasper Therapeutics
JSPR
68 hedge funds and large institutions have $56.1M invested in Jasper Therapeutics in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 30 closing their positions.
88% more call options, than puts
Call options by funds: $179K | Put options by funds: $95K
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
17.49% less ownership
Funds ownership: 104.36% → 86.87% (-17%)
22% less funds holding
Funds holding: 87 → 68 (-19)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
60% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 30
83% less capital invested
Capital invested by funds: $335M → $56.1M (-$278M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$4.13M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.46M |
| 3 |
LPC
Lion Point Capital
New York
|
+$762K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$546K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$15.3M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$12.5M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.55M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$7.48M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.89M |
JSPR Hedge Fund Activity: Q1 2025 in Review
68 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2025, worth a combined $56.1M — down 83% from $335M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of JSPR and 12 opened new positions — a net loss of 18 holders — while 23 trimmed existing stakes and 21 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $4.13M. The largest seller was Braidwell, exiting entirely with an estimated $15.3M sold.
- 68 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2025, down from 87 in Q4 2024.
- Funds reported $56.1M of Jasper Therapeutics stock for Q1 2025, down 83% quarter-over-quarter.
- 12 funds opened new Jasper Therapeutics positions in Q1 2025 and 30 closed out, a net change of -18 holders.
- The largest Jasper Therapeutics buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $4.13M added.
- The largest Jasper Therapeutics seller in Q1 2025 was Braidwell, an estimated $15.3M sold.
Based on aggregated 13F filings for Q1 2025.